Skip to content

The application of 68Ga-FAPI and 18F-FDG PET/CT in the Gastrointestinal Mucinous Adenocarcinoma or Signet Ring Cell Carcinoma

The application of 68Ga-FAPI and 18F-FDG PET/CT in the Gastrointestinal Mucinous Adenocarcinoma or Signet Ring Cell Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066462
Enrollment
Unknown
Registered
2022-12-06
Start date
2022-12-15
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Mucinous Adenocarcinoma or Signet Ring Cell Carcinoma

Interventions

Index test:maximum standard uptake value(SUVmax),sensitivity, specificity, accuracy

Sponsors

Fudan University, Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (i) Aged >=18 years old; (ii) patients with newly diagnosed or recurrent Gastrointestinal mucinous adenocarcinoma (MAC) and signet ring cell carcinoma (SRCC) ; (iii) patients who had scheduled both 18F-FDG and 68Ga-DOTA-FAPI-04 PET/CT scans; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion criteria

Exclusion criteria: (i) pregnancy woman; (2)patients with a history of other malignant tumors; (3)patients who did not willing to participant in this study or did not sign the informed consent.

Design outcomes

Primary

MeasureTime frame
sensitivity;

Secondary

MeasureTime frame
specificity;accuracy;

Countries

China

Contacts

Public ContactShaoli Song

Fudan University, Shanghai Cancer Center

song-shaoli@163.com+86 18121299622

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026